TY - JOUR ID - 702002 TI - Effect of Fluvoxamine on Interleukin-6 Levels in COVID-19 Patients Hospitalized in ICU: A Randomized Clinical Trial JO - TANAFFOS (Respiration) JA - RSPR LA - en SN - 1735-0344 AU - Safa, Mitra AU - Hashemian, Seyed MohammadReza AU - Abedi, Mohsen AU - Malek Mohammad, Majid AU - Ashraf Zadeh, Mahshid AU - Ghassem Boroujerdi, Fatemeh AU - Haji Zadeh, Farzaneh AU - Mirab Zadeh Ardekani, Bamdad AD - Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Physiotherapy Research Center, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Tracheal Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Department of Anesthesiology and Intensive Care, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. AD - Massih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Y1 - 2022 PY - 2022 VL - 21 IS - 2 SP - 214 EP - 220 KW - COVID-19 KW - Cytokine KW - Fluvoxamine KW - Interleukin-6 KW - IL-6 KW - CRP DO - N2 - Background: Reviewing the laboratory studies, we observe some drugs with other specified applications, which cause serious inhibitory immune responses in the body. Selective Serotonin Reuptake Inhibitors (SSRIs) are among these drugs. Therefore, the current research aimed to evaluate the effectiveness of one of the SSRI drugs called fluvoxamine on the cytokine levels in COVID-19 patients. Materials and Methods: The current research included 80 patients with COVID-19 hospitalized in ICU in Massih Daneshvari Hospital. They were entered into the research by an accessible method of sampling and then divided into two groups randomly. One of the groups underwent the treatment with fluvoxamine as the experimental group and the other group did not receive fluvoxamine as the control group. Interleukin-6 (IL-6) and CRP levels were measured before the onset of fluvoxamine consumption and when discharging from the hospital in all members of the sample group. Results: The current study showed that IL-6 levels increased, while CRP levels decreased in the experimental group significantly (P-value≤ 0.01). After consuming fluvoxamine, IL-6 and CRP levels were higher and lower in the females compared to the males, respectively. Conclusion: Considering the effectiveness of fluvoxamine on IL-6 and CRP in COVID-19 patients, it may ultimately come true to use this drug to improve both psychological and physical conditions simultaneously and leave the COVID-19 pandemic behind with less pathology. UR - https://www.tanaffosjournal.ir/article_702002.html L1 - https://www.tanaffosjournal.ir/article_702002_6c8e78cc3db1ade111a028bd3f868a78.pdf ER -